Wedge Industrial (000534.SZ) plans to jointly invest with Qingdao Honghua to establish an industrial acquisition fund.
(000534.SZ) released an announcement, aiming to fully leverage the company's strengths in aircraft engines, gas turbines, and many other fields.
Wedge Industrial (000534.SZ) announced that in order to fully leverage the company's technical advantages in the aerospace engine and gas turbine industries (referred to as the "two engines"), and to expand its industrial chain capabilities, enhance business levels, and improve operating performance, the company plans to sign a cooperation agreement with Qingdao Honghua Private Equity Fund Management Co., Ltd. (referred to as "Qingdao Honghua") to establish an industrial merger and acquisition fund.
The total subscribed capital of the merger and acquisition fund is 1 billion RMB, with the company as a limited partner subscribing 500 million RMB, accounting for 50.00% of the total subscribed capital of the partnership; Qingdao Honghua as a general partner subscribing 1 million RMB, accounting for 0.10% of the total subscribed capital of the partnership; Qingdao Honghua designated investment entity subscribing 4.99 billion RMB, accounting for 49.90% of the total subscribed capital of the partnership.
The company will jointly participate in the investment and establishment of the fund with professional institutions, fully leveraging the professional capabilities and resource advantages of all parties, achieving capital appreciation through project investments, serving the company's long-term strategic development goals, and enhancing the company's overall competitiveness. At the same time, through the company's control of the assets to be acquired through mergers and acquisitions, the company can help expand its industrial chain capabilities, enhance business levels, improve operating performance, and create more value for the company and its shareholders.
Related Articles

The era of buying blindly with closed eyes is over! The strategy of the seven giants in US stocks of holding together has failed. Wall Street calls for buying separately in 2026.

TRANSTHERA-B (02617) announced clinical data of single-agent treatment with tigeroxitinib in patients with advanced cholangiocarcinoma at the 2026 American Clinical Oncology Society Gastrointestinal Tumor Symposium.

APAC RESOURCES (01104) Announces Profit Forecast - Expects Shareholders' Net Profit for the first half of the 25/26 fiscal year to be approximately HK$1.4 billion to HK$1.9 billion, turning from a loss to a profit year on year.
The era of buying blindly with closed eyes is over! The strategy of the seven giants in US stocks of holding together has failed. Wall Street calls for buying separately in 2026.

TRANSTHERA-B (02617) announced clinical data of single-agent treatment with tigeroxitinib in patients with advanced cholangiocarcinoma at the 2026 American Clinical Oncology Society Gastrointestinal Tumor Symposium.

APAC RESOURCES (01104) Announces Profit Forecast - Expects Shareholders' Net Profit for the first half of the 25/26 fiscal year to be approximately HK$1.4 billion to HK$1.9 billion, turning from a loss to a profit year on year.

RECOMMEND

Patent Cliff Looms As Pharmaceutical Sector Prepares For A New Round Of Asset Competition
10/01/2026

Goldman Sachs Remains Bullish On China Equities: AI And Overseas Expansion To Drive Earnings, MSCI China Seen Rising 20% In 2026
10/01/2026

“A+H” Popularity Continues As Multiple A‑Share Companies Announce Hong Kong Listings At The Start Of The Year
10/01/2026


